Logo-jnp
J Nephropathol. 2020;9(4): e36. doi: 10.34172/jnp.2020.36

Short-Review

SARS-CoV-2 and Fabry nephropathy: potential risks and the pathophysiological perspective

Hernán Trimarchi 1 * ORCID

Cited by CrossRef: 2

1- Al-kuraishy H, Al-Gareeb A, Almulaiky Y, Cruz-Martins N, El-Saber Batiha G. Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity. European Journal of Pharmacology. 2021;904:174196 [Crossref]
2- Laney D, Germain D, Oliveira J, Burlina A, Cabrera G, Hong G, Hopkin R, Niu D, Thomas M, Trimarchi H, Wilcox W, Politei J, Ortiz A. Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. 2020;13(6):913 [Crossref]